What is Biogen's felzartamab (pmn) — intangible assets:?

Biogen (BIIB) reported felzartamab (pmn) — intangible assets: of $265.00M in Q2 2024.

What does felzartamab (pmn) — intangible assets: mean?

The total accounting value of intellectual property and development rights tied to the Felzartamab drug candidate.

Discontinued — last reported Q2 '24

Products & Services · Intangible assets:

Felzartamab (PMN) — Intangible assets:

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ2 2024

Last reportedQ2 2024Feb 6, 2026

Rolls up toIntangibles (Net)

How to read this metric

An increase typically reflects additional investment or acquisition of development rights, while a decrease may indicate amortization, impairment charges, or successful commercialization transitions.

Detailed definition

This metric represents the capitalized value of intangible assets specifically associated with the Felzartamab (PMN) pro...

Peer comparison

Comparable to capitalized in-process research and development (IPR&D) or intangible assets reported by other biopharmaceutical firms for specific pipeline assets.

Metric ID: biib_segment_felzartamab_pmn_intangible_assets

Historical Data

1 periods

	Q2 '24
Value	$265.00M

Similar Metrics at Other Companies

InsmedINSM View metric

ViatrisVTRS View metric

InsmedINSM View metric

Vertex PharmaceuticalsVRTX View metric

ViatrisVTRS View metric

Becton, Dickinson and CompanyBDX View metric

Frequently Asked Questions

What is Biogen's felzartamab (pmn) — intangible assets:?: Biogen (BIIB) reported felzartamab (pmn) — intangible assets: of $265.00M in Q2 2024.
What does felzartamab (pmn) — intangible assets: mean?: The total accounting value of intellectual property and development rights tied to the Felzartamab drug candidate.